Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Argos Therapeutics has said that dosing has been initiated in a phase I/II trial to test the activity and safety of its B-cell chronic lymphocytic leukemia treatment.
Subscribe to our email newsletter
Parsons looks to increase shareholder value with his business acumen, financing and acquisitions background beginning in the 1980s. These talents align perfectly to the vision XcelPlus has for it technologies, some of which are now ready for commercial, retail and distribution markets in different parts of the world.
Parsons said, “Timing for a global vision of entities related to alternative and renewable fuels, in conjunction with our current technologies and products, should allow XcelPlus Global to become a major power in solving the most obvious crisis called energy.